2014
DOI: 10.3389/fneur.2014.00025
|View full text |Cite
|
Sign up to set email alerts
|

Methods for Surgical Targeting of the STN in Early-Stage Parkinson’s Disease

Abstract: Patients with Parkinson's disease (PD) experience progressive neurological decline, and future interventional therapies are thought to show most promise in early stages of the disease. There is much interest in therapies that target the subthalamic nucleus (STN) with surgical access. While locating STN in advanced disease patients (Hoehn-Yahr Stage III or IV) is well understood and routinely performed at many centers in the context of deep brain stimulation surgery, the ability to identify this nucleus in earl… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
21
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
5
2
1

Relationship

3
5

Authors

Journals

citations
Cited by 19 publications
(21 citation statements)
references
References 16 publications
0
21
0
Order By: Relevance
“…This study also suggests that it is likely possible to accurately target and implant bilateral STN deep brain stimulating electrodes in patients with early stage PD and very mild symptomatology [12, 14]. In addition to intraoperative microelectrode recordings and post-operative imaging verification of lead placement, all implanted subjects underwent lead interrogation of all four contacts on each side of the brain in the off medication state and all subjects had at least one efficacious contact.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…This study also suggests that it is likely possible to accurately target and implant bilateral STN deep brain stimulating electrodes in patients with early stage PD and very mild symptomatology [12, 14]. In addition to intraoperative microelectrode recordings and post-operative imaging verification of lead placement, all implanted subjects underwent lead interrogation of all four contacts on each side of the brain in the off medication state and all subjects had at least one efficacious contact.…”
Section: Discussionmentioning
confidence: 99%
“…Complete descriptions of the trial design, methods, recruitment of subjects, study procedures, consent process, surgical technique, targeting procedure, intraoperative microelectrode recording procedure, and baseline subject characteristics have been previously reported and are briefly reviewed as follows [1014]. …”
Section: Methodsmentioning
confidence: 99%
“…However, the theoretical concept of VTA modelling constitutes a simplification that neglects factors like fiber orientation (Anderson et al, 2019). Regarding the concept of predicting effects of deep brain stimulation in relation to the anatomical target area there have been several approaches in the past, such as investigating lead positions (Delcour et al, 2011;Camalier et al, 2014;Barbe et al, 2018;Dafsari et al, 2018), the creation of probabilistic sweet spots (Eisenstein et al, 2014;Dembek et al, 2017;Dembek et al, 2019b;Reich et al, 2019), and the estimation of beneficial Running head: Networks in DBS-induced dysarthria connectivity profiles (Horn et al, 2017;Al-Fatly et al, 2019). In this study, we focused on providing an atlas structure that is easy to implement in planning and programming software and therefore decided to base our predictive model on an approach introduced by Baldermann et al (Baldermann et al, 2019).…”
Section: Methodological Considerations and Limitationsmentioning
confidence: 99%
“…The researchers concluded that DBS is well tolerated in very early PD. In a separate publication, they reported that traditional surgical methods, including image‐guided targeting, microelectrode recording (MER), and macrostimulation, enable accurate identification and targeting of the STN in PD patients with minimal motor impairment . Together, these studies form the basis for an upcoming, recently FDA‐approved, double‐blind, placebo‐controlled, phase III clinical trial of STN DBS in patients with early‐stage PD.…”
Section: New Treatments and Discoveriesmentioning
confidence: 99%